SpectRx/Healthdyne expect 1997 510(k) submission for non-invasive infant jaundice test -- SpectRx IPO.
This article was originally published in The Gray Sheet
SPECTRX 510(K) FOR NON-INVASIVE INFANT JAUNDICE TEST will be submitted to FDA this year by partner Healthdyne Technologies, SpectRx says in a June 11 preliminary prospectus for an initial public offering. A prototype version of the test, which is intended to provide bilirubin measurements at the point of care through the use of reflection spectroscopy, currently is being evaluated in pilot trials at three centers.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.